Pioglitazona (Thiazolidinedionas)
DOI:
https://doi.org/10.58713/rf.v2i1.4Keywords:
Diabetes, Farmacología, Pioglitazona, Mujeres embarazadasAbstract
La pioglitazona es una thiazolidinediona, útil en el tratamiento de la Diabetes Mellitus tipo2 (DMT2) cuyo mecanismo de acción es mediado por el receptor ppar-gamma. Tiene un efecto normo regulador de la glucemia y mejora la sensibilidad tisular en pacientes con resistencia tisular periférica a la insulina, mediante la regulación génica de las vías metabólicas del almacenamiento y liberación de lípidos. Se puede emplear como monoterapia o combinada con metformina o sulfonilureas. Se ha demostrado que mejora la función endotelial, la ovulación, la resistencia a la insulina y disminuya la esteatosis y la fibrosis hepática. Es teratógeno en modelos animales y en las mujeres embarazadas, causa retraso en la maduración fetal, por lo que, en caso de embarazo, debe ser remplazada por otro sensibilizador de insulina
References
Lalloyer F, Staels B. Fibrates, Glitazones, and Peroxisome Proliferator–Activated Receptors. Arterioscler Thromb Vasc Biol. 2010;30(5):894–9.
Gale EAM. Lessons from the glitazones: a story of drug development. Lancet [Internet]. 2001 Jun 9;357(9271):1870–5. Available from: https://doi.org/10.1016/S0140- 6736(00)04960-6
Nissen SE. The rise and fall of rosiglitazone. Eur Heart J [Internet]. 2010;31(7):773–6. Available from: https://doi.org/10.1093/ eurheartj/ehq016
Woodcock J, Sharfstein JM, Hamburg M. Regulatory Action on Rosiglitazone by the U.S. Food and Drug Administration. N Engl J Med [Internet]. 2010;363(16):1489–91. Available from: https://doi.org/10.1056/ NEJMp1010788
Nanjan MJ, Mohammed M, Prashantha Kumar BR, Chandrasekar MJN. Thiazolidinediones as antidiabetic agents: A critical review. Bioorg Chem [Internet]. 2018;77:548–67. Available from: https://doi.org/10.1016/j. bioorg.2018.02.009
Chang Y-H, Yen S-J, Chang Y-H, Wu W-J, Lin K-D. Pioglitazone and statins lower incidence of Parkinson disease in patients with diabetes mellitus. Eur J Neurol. 2021 Feb;28(2):430–7.
Lian J, Fu J. Pioglitazone for NAFLD Patients With Prediabetes or Type 2 Diabetes Mellitus: A Meta-Analysis. Vol. 12, Frontiers in endocrinology. 2021. p. 615409.
Hadamitzky C, Rennekampff HO, Pabst R, Radtke C, Vogt PM. Lymphatic regeneration in meshed skin grafts. Burns [Internet]. 2012;38(3):461–3. Available from: https:// www.sciencedirect.com/science/article/pii/ S0305417911003767
Feig DS, Briggs GG, Koren G. Oral antidiabetic agents in pregnancy and lactation: A paradigm shift? Ann Pharmacother. 2007;41(7– 8):1174–80.
Lebovitz HE. Thiazolidinediones: the Forgotten Diabetes Medications. Curr Diab Rep. 2019 Nov;19(12):151.
Ondrey FG. Pioglitazone, Nuclear Receptors, and Aerodigestive Prevention. Vol. 12, Cancer prevention research (Philadelphia, Pa.). United States; 2019. p. 641–4.
Rojewska A, Karewicz A, Karnas K, Wolski K, Zajac M, Kamiński K, et al. Pioglitazone-loaded nanostructured hybrid material for skin ulcer treatment. Materials (Basel). 2020;13(9).
El-Fayoumi S, Mansour R, Mahmoud A, Fahmy A, Ibrahim I. Pioglitazone Enhances β-Arrestin2 Signaling and Ameliorates Insulin Resistance in Classical Insulin Target Tissues. Pharmacology. 2021;106(7–8):409–17.
Hu Y, Tao R, Chen L, Xiong Y, Xue H, Hu L, et al. Exosomes derived from pioglitazonepretreated MSCs accelerate diabetic wound healing through enhancing angiogenesis. J Nanobiotechnology. 2021 May;19(1):150
Nesti L, Tricò D, Mengozzi A, Natali A. Rethinking pioglitazone as a cardioprotective agent: a new perspective on an overlooked drug. Cardiovasc Diabetol. 2021 May;20(1):109.
Liu C-H, Lee T-H, Lin Y-S, Sung P-S, Wei Y-C, Li Y-R. Pioglitazone and PPAR-γ modulating treatment in hypertensive and type 2 diabetic patients after ischemic stroke: a national cohort study. Cardiovasc Diabetol. 2020 Jan;19(1):2.
Budde K, Neumayer H-H, Fritsche L, Sulowicz W, Stompôr T, Eckland D. The pharmacokinetics of pioglitazone in patients with impaired renal function. Vol. 55, BCPBritish Journal of Clinical Pharmacology. 2003.
Ha J, Choi D-W, Kim KY, Nam CM, Kim E. Pioglitazone use associated with reduced risk of the first attack of ischemic stroke in patients with newly onset type 2 diabetes: a nationwide nested case-control study. Cardiovasc Diabetol. 2021 Jul;20(1):152.
Forst T, Hanefeld M, Pfützner A. Review of approved pioglitazone combinations for type 2 diabetes. Expert Opin Pharmacother [Internet]. 2011;12(10):1571–84. Available from: https://doi.org/10.1517/14656566.201 1.567266
Eckland DA, Danhof M. Clinical pharmacokinetics of pioglitazone. Exp Clin Endocrinol Diabetes. 2000;108(Sup. 2):234–42.
Ripamonti E, Azoulay L, Abrahamowicz M, Platt RW, Suissa S. Pioglitazone and bladder cancer: improving research methods. Vol. 37, Diabetic medicine : a journal of the British Diabetic Association. England; 2020. p. 898–9.
Proskocil BJ, Fryer AD, Jacoby DB, Nie Z. Pioglitazone prevents obesity-related airway hyperreactivity and neuronal M(2) receptor dysfunction. Am J Physiol Lung Cell Mol Physiol. 2021 Jul;321(1):L236–47
Hasegawa H, Yatomi K, Mitome-Mishima Y, Miyamoto N, Tanaka R, Oishi H, et al. Pioglitazone Prevents Hemorrhagic Infarction After Transient Focal Ischemia in Type 2 Diabetes. Neurosci Res. 2021 Sep;170:314– 21
Sánchez-Valle R. Pioglitazone for prevention of cognitive impairment: results and lessons. Lancet Neurol. 2021 Jul;20(7):500–2.
Amirian M, Shariat Moghani S, Jafarian F, Mirteimouri M, Nikdoust S, Niroumand S, et al. Combination of pioglitazone and clomiphene citrate versus clomiphene citrate alone for infertile women with the polycystic ovarian syndrome. BMC
Chyzhyk V, Kozmic S, Brown AS, Hudgins LC, Starc TJ, Davila AD, et al. Extreme hypertriglyceridemia: Genetic diversity, pancreatitis, pregnancy, and prevalence. J Clin Lipidol. 2019;13(1):89–99.
